Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Namilumab for chronic pulmonary sarcoidosis
NL-OMON60143Phase 2Completed
- Sponsor
- Kinevant Sciences
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Chronic Pulmonary Sarcoidosis comparing namilumab with placebo (2 arms). Primary endpoint: Proportion of subjects with a rescue event during double-blind period. Started Nov 2022; status: completed.
02
Drugs
namilumab
03
Conditions
Chronic Pulmonary Sarcoidosis
Beyond the preview
Go deeper on NL-OMON60143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60143.